Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Thyroid Research
Published in: Thyroid Research 1/2024

Open Access 01-12-2024 | Pituitary Adenoma | Case Report

Clinical characteristics and outcomes of patients with TSH-secreting pituitary adenoma and Graves’ disease - a case report and systematic review

Authors: Adeel Ahmad Khan, Shahd I. Ibrahim, Fateen Ata, Bara Wazwaz, Mohammad Abdulalim Hanoun, Sirajeddin Belkhair, Zaina Seros Rohani, Zeinab Dabbous

Published in: Thyroid Research | Issue 1/2024

Login to get access

Abstract

Background

Coexistence of TSH-secreting pituitary adenoma (TSHoma) and Graves’ disease (GD) is rare and complicates the management decision.

Methods

We present a case of the co-existence of TSHoma and GD. In addition, we systematically searched articles describing TSHoma and GD in the same patient published until 20th March 2023, using Pubmed, Scopus and Embase.

Case presentation

A 46-year-old man presented with symptoms of thyrotoxicosis. His thyroid function tests showed serum TSH 3.35 (reference range 0.3–4.2) mIU/L, FT3 19.7 (3.7–6.4) pmol/L, and FT4 68.9 (11-23.3) pmol/L. The serum TSH receptor antibody was 11.5 mIU/L (positive at ≥ 1.75 mIU/L). Pituitary magnetic resonance imaging showed macroadenoma compressing the optic chiasm. The patient underwent trans-sphenoidal resection of pituitary adenoma. Postoperatively, he remained on maintenance carbimazole and octreotide.

Results

Fourteen articles comprising 15 patients were identified from the systemic search. A total of 16 patients (including the current case) were included in the systematic review. The mean (± SD) age at diagnosis was 41 ± 13.6 years. The majority were females (75%). The median (IQR) TSH was 1.95 (0.12–5.5) mIU/L, the median (IQR) free T3 was 11.7 (7.6–19.7) pmol/L and the median (IQR) free T4 level was 47.6 (33.3–64.4) pmol/L. Ten (76.9%) patients had positive TSH receptor antibody levels. 84.6% had pituitary macroadenoma. Pituitary surgery was performed in 12 (75%) patients. At the last follow-up, 4 (25%) patients had complete resolution of symptoms after pituitary surgery, 3 (18.7%) were on maintenance treatment with thionamides for GD, 1 (6.25%) on beta-blockers and 1 (6.25%) on somatostatin analog.

Conclusion

TSHoma and GD can co-exist, and it is essential to identify this rare association as it can significantly impact treatment strategies.
Literature
1.
Tjörnstrand A, Nyström HF. DIAGNOSIS OF ENDOCRINE DISEASE: diagnostic approach to TSH-producing pituitary adenoma. Eur J Endocrinol. 2017;177(4):R183–97.CrossRefPubMed
2.
Ónnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab. 2013;98(2):626–35.CrossRefPubMed
3.
Önnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF. National Incidence and Prevalence of TSH-Secreting Pituitary adenomas in Sweden. J Clin Endocrinol Metabolism. 2013;98(2):626–35.CrossRef
4.
Wynne AG, Gharib H, Scheithauer BW, Davis DH, Freeman SL, Horvath E. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med. 1992;92(1):15–24.CrossRefPubMed
5.
Després N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem. 1998;44(3):440–54.CrossRefPubMed
6.
Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76–82.CrossRefPubMedPubMedCentral
7.
Bell L, Hunter AL, Kyriacou A, Mukherjee A, Syed AA. Clinical diagnosis of Graves’ or non-graves’ hyperthyroidism compared to TSH receptor antibody test. Endocr Connect. 2018;7(4):504–10.CrossRefPubMedPubMedCentral
8.
Arai N, Inaba M, Ichijyo T, Kagami H, Mine Y. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves’ Disease: a case report. J Med Case Rep. 2017;11(1):9.CrossRefPubMedPubMedCentral
9.
Kamoun M, d’Herbomez M, Lemaire C, Fayard A, Desailloud R, Huglo D, Wemeau J-L. Coexistence of thyroid-stimulating hormone-secreting Pituitary Adenoma and Graves’ hyperthyroidism. Eur Thyroid J. 2014;3(1):60–4.CrossRefPubMed
10.
Li J, Tan H, Huang J, Luo D, Tang Y, Yu R, Huang H. Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves’ Disease. Med (Baltim). 2018;97(24):e11047.CrossRef
11.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
12.
JBI. : The Joanna Briggs Institute Critical Appraisal tools.
13.
Novruzov F, Aliyev A, Wan MYS, Syed R, Mehdi E, Aliyeva I, Giammarile F, Bomanji JB, Kayani I. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. 2021;5(1):10.CrossRefPubMedPubMedCentral
14.
Diri H, Şimşek Y, Karaca Z, Keleştimur F. Thyrotropinomas: presentation of three cases and review of literature. ERCİYES Med J. 2016;38(1):32–7.CrossRef
15.
Fu J, Wu A, Wang X, Guan H. Concurrent Graves’ Disease and TSH Secreting Pituitary Adenoma Presenting Suppressed Thyrotropin Levels: A Case Report and Review of the Literature. Front Endocrinol 2020, 11.
16.
Kageyama K, Ikeda H, Sakihara S, Nigawara T, Terui K, Tsutaya S, Matsuda E, Shoji M, Yasujima M, Suda T. A case of thyrotropin-producing pituitary adenoma, accompanied by an increase in anti-thyrotropin receptor antibody after Tumor resection. J Endocrinol Investig. 2007;30(11):957–61.CrossRef
17.
Kamoi K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R, Arai O, Takasu N, Yamada T. Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves’ Disease in a middle-aged woman. Acta Endocrinol (Copenh). 1985;110(3):373–82.PubMed
18.
Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hirano H, Nakano S, Tei C. Thyrotropin-producing pituitary adenoma associated with Graves’ Disease. Eur J Endocrinol Eur J Endocrinol. 2004;151(5):587–94.CrossRefPubMed
19.
Lee MT, Wang CY. Concomitant Graves hyperthyroidism with thyrotrophin-secreting pituitary adenoma. South Med J. 2010;103(4):347–9.CrossRefPubMed
20.
O’Donnell J, Hadden DR, Weaver JA, Montgomery DA. Thyrotoxicosis recurring after surgical removal of a thyrotrophin-secreting pituitary tumour. Proc R Soc Med. 1973;66(5):441–2.PubMedPubMedCentral
21.
Ogawa Y, Tominaga T. Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves’ Disease: a case report. J Med Case Rep. 2013;7:27.CrossRefPubMedPubMedCentral
22.
Okuyucu K, Alagoz E, Arslan N, Taslipinar A, Deveci MS, Bolu E. Thyrotropinoma with Graves’ Disease detected by the fusion of indium-111 octreotide scintigraphy and pituitary magnetic resonance imaging. Indian J Nucl Med. 2016;31(2):141–3.CrossRefPubMedPubMedCentral
23.
Quinn M, Bashari W, Smith D, Gurnell M, Agha A. A remarkable case of thyrotoxicosis initially caused by graves’ Disease followed by a probable TSHoma – a case report. BMC Endocr Disorders. 2020;20(1):133.CrossRef
24.
SANDLER R. Recurrent hyperthyroidism in an acromegalic patient previously treated with Proton Beam Irradiation: Graves’ Disease as probable etiology based on Follow-Up observations. J Clin Endocrinol Metabolism. 1976;42(1):163–8.CrossRef
25.
Huber GK, Concepcion ES, Graves PN, Davies TF. Positive regulation of human thyrotropin receptor mRNA by thyrotropin. J Clin Endocrinol Metab. 1991;72(6):1394–6.CrossRefPubMed
26.
Chung J, Park ES, Kim D, Suh JM, Chung HK, Kim J, Kim H, Park SJ, Kwon OY, Ro HK, et al. Thyrotropin modulates interferon-gamma-mediated intercellular adhesion molecule-1 gene expression by inhibiting Janus kinase-1 and signal transducer and activator of transcription-1 activation in thyroid cells. Endocrinology. 2000;141(6):2090–7.CrossRefPubMed
27.
Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Kawabe Y, Ishikawa N, Ito K, Nagataki S. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology. 1996;137(8):3163–9.CrossRefPubMed
28.
De Herdt C, Philipse E, De Block C. ENDOCRINE TUMOURS: Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases. Eur J Endocrinol. 2021;185(2):R65–r74.CrossRefPubMed
29.
Brucker-Davis Fo, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metabolism. 1999;84(2):476–86.CrossRef
30.
Han R, Shen L, Zhang J, Xie J, Fang W, Sun Q, Bian L, Zhou Y, Wang S, Ning G, et al. Diagnosing thyrotropin-secreting pituitary adenomas by short-term somatostatin Analogue Test. Thyroid®. 2020;30(9):1236–44.CrossRefPubMed
31.
Cossu G, Daniel RT, Pierzchala K, Berhouma M, Pitteloud N, Lamine F, Colao A, Messerer M. Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management. Pituitary. 2019;22(1):79–88.CrossRefPubMed
32.
Liu J, Yang Y, Duan L, Chai X, Zhu H, Deng K, Lian X, Yao Y. Combination of transsphenoidal endoscopic Surgery and presurgical somatostatin analogs in thyrotropin (TSH)-secreting pituitary adenomas: treatment outcome and long-term remission at a single pituitary center. Front Endocrinol (Lausanne). 2022;13:1061029.CrossRefPubMed
33.
Byun J, Kim JH, Kim YH, Cho YH, Hong SH, Kim CJ. Thyroid-stimulating hormone-secreting Pituitary adenomas: single institutional experience of 14 consecutive cases. J Korean Neurosurg Soc. 2020;63(4):495–503.CrossRefPubMedPubMedCentral
34.
Herguido NG, Fuentes ED, Venegas-Moreno E, Maorad LB, Flores-Martinez A, Ruiz PR, Dueñas MC, Roldán F, Fajardo E, Ruiz-Valdepeñas EC, et al. Surgical Outcome and Treatment of Thyrotropin-secreting pituitary tumors in a Tertiary Referral Center. World Neurosurg. 2019;130:e634–9.CrossRefPubMed
35.
Malchiodi E, Profka E, Ferrante E, Sala E, Verrua E, Campi I, Lania AG, Arosio M, Locatelli M, Mortini P, et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary Surgery and irradiation. J Clin Endocrinol Metabolism. 2014;99(6):2069–76.CrossRef
36.
Luo P, Zhang L, Yang L, An Z, Tan H. Progress in the Pathogenesis, diagnosis, and treatment of TSH-Secreting pituitary neuroendocrine Tumor. Front Endocrinol (Lausanne). 2020;11:580264.CrossRefPubMed
37.
Beck-Peccoz P, Persani L, Lania A. Thyrotropin-Secreting Pituitary Adenomas. In: Endotext edn. Edited by Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J South Dartmouth (MA): MDText.com, Inc.
Metadata
Title
Clinical characteristics and outcomes of patients with TSH-secreting pituitary adenoma and Graves’ disease - a case report and systematic review
Authors
Adeel Ahmad Khan
Shahd I. Ibrahim
Fateen Ata
Bara Wazwaz
Mohammad Abdulalim Hanoun
Sirajeddin Belkhair
Zaina Seros Rohani
Zeinab Dabbous
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Thyroid Research / Issue 1/2024
Electronic ISSN: 1756-6614
DOI
https://doi.org/10.1186/s13044-023-00184-2

Other articles of this Issue 1/2024

Thyroid Research 1/2024 Go to the issue

Review

When to settle for SETTLE! A lesson learned from our cases

Research

Radiofrequency ablation for thyroid nodules in Ecuador: a cross-sectional study

Research

Multi-element analysis of metals in human pathological and unchanged thyroid glands – pilot study

Research

TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases

Case Report

Hyalinizing trabecular tumor of the thyroid

Review

Thyroid storm in pregnancy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits